vs
弗雷斯特研究公司（FORR）与MEDIFAST INC（MED）财务数据对比。点击上方公司名可切换其他公司
弗雷斯特研究公司的季度营收约是MEDIFAST INC的1.3倍（$101.1M vs $75.1M），弗雷斯特研究公司同比增速更快（-6.5% vs -36.9%），弗雷斯特研究公司自由现金流更多（$-4.3M vs $-6.6M），过去两年弗雷斯特研究公司的营收复合增速更高（0.5% vs -34.4%）
福雷斯特研究公司是一家全球领先的研究咨询机构，主营业务涵盖行业研究、管理咨询与行业峰会举办，客户群体包括全球大型企业、科技公司与消费领域领军企业，公司总部位于美国马萨诸塞州剑桥市。
迈德福斯特是一家总部位于美国马里兰州巴尔的摩的营养减重企业，该公司研发、分销并销售减重及健康相关产品，销售渠道涵盖官方网站、多层次营销、电话销售以及品牌加盟减重诊所。
FORR vs MED — 直观对比
营收规模更大
FORR
是对方的1.3倍
$75.1M
营收增速更快
FORR
高出30.4%
-36.9%
自由现金流更多
FORR
多$2.4M
$-6.6M
两年增速更快
FORR
近两年复合增速
-34.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $101.1M | $75.1M |
| 净利润 | $-33.9M | — |
| 毛利率 | 56.7% | 69.4% |
| 营业利润率 | -36.6% | -10.4% |
| 净利率 | -33.5% | — |
| 营收同比 | -6.5% | -36.9% |
| 净利润同比 | -7941.4% | — |
| 每股收益（稀释后） | $-1.75 | $-1.64 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FORRMED
| Q4 25 | $101.1M | $75.1M | ||
| Q3 25 | $94.3M | $89.4M | ||
| Q2 25 | $111.7M | $105.6M | ||
| Q1 25 | $89.9M | $115.7M | ||
| Q4 24 | $108.0M | $119.0M | ||
| Q3 24 | $102.5M | $140.2M | ||
| Q2 24 | $121.8M | $168.6M | ||
| Q1 24 | $100.1M | $174.7M |
净利润FORRMED
| Q4 25 | $-33.9M | — | ||
| Q3 25 | $-2.1M | $-2.3M | ||
| Q2 25 | $3.9M | $2.5M | ||
| Q1 25 | $-87.3M | $-772.0K | ||
| Q4 24 | $432.0K | — | ||
| Q3 24 | $-5.8M | $1.1M | ||
| Q2 24 | $6.3M | $-8.2M | ||
| Q1 24 | $-6.7M | $8.3M |
毛利率FORRMED
| Q4 25 | 56.7% | 69.4% | ||
| Q3 25 | 60.0% | 69.5% | ||
| Q2 25 | 55.5% | 72.6% | ||
| Q1 25 | 55.9% | 72.8% | ||
| Q4 24 | 58.8% | 74.1% | ||
| Q3 24 | 60.5% | 75.4% | ||
| Q2 24 | 57.3% | 73.2% | ||
| Q1 24 | 54.9% | 72.8% |
营业利润率FORRMED
| Q4 25 | -36.6% | -10.4% | ||
| Q3 25 | 4.7% | -4.6% | ||
| Q2 25 | 6.2% | -1.0% | ||
| Q1 25 | -97.5% | -1.1% | ||
| Q4 24 | -0.5% | 0.6% | ||
| Q3 24 | -0.7% | 1.5% | ||
| Q2 24 | 9.3% | -4.7% | ||
| Q1 24 | -9.3% | 4.5% |
净利率FORRMED
| Q4 25 | -33.5% | — | ||
| Q3 25 | -2.3% | -2.5% | ||
| Q2 25 | 3.5% | 2.3% | ||
| Q1 25 | -97.1% | -0.7% | ||
| Q4 24 | 0.4% | — | ||
| Q3 24 | -5.7% | 0.8% | ||
| Q2 24 | 5.2% | -4.8% | ||
| Q1 24 | -6.7% | 4.8% |
每股收益（稀释后）FORRMED
| Q4 25 | $-1.75 | $-1.64 | ||
| Q3 25 | $-0.11 | $-0.21 | ||
| Q2 25 | $0.20 | $0.22 | ||
| Q1 25 | $-4.62 | $-0.07 | ||
| Q4 24 | $0.02 | $0.08 | ||
| Q3 24 | $-0.30 | $0.10 | ||
| Q2 24 | $0.33 | $-0.75 | ||
| Q1 24 | $-0.35 | $0.76 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $63.3M | $167.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $126.5M | $198.9M |
| 总资产 | $404.0M | $248.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FORRMED
| Q4 25 | $63.3M | $167.3M | ||
| Q3 25 | $65.1M | $173.5M | ||
| Q2 25 | $67.8M | $162.7M | ||
| Q1 25 | $75.6M | $164.6M | ||
| Q4 24 | $56.1M | $162.3M | ||
| Q3 24 | $62.8M | $170.0M | ||
| Q2 24 | $58.9M | $163.5M | ||
| Q1 24 | $61.4M | $156.4M |
股东权益FORRMED
| Q4 25 | $126.5M | $198.9M | ||
| Q3 25 | $157.7M | $214.7M | ||
| Q2 25 | $159.5M | $216.0M | ||
| Q1 25 | $147.4M | $211.0M | ||
| Q4 24 | $229.5M | $210.1M | ||
| Q3 24 | $234.3M | $207.3M | ||
| Q2 24 | $237.1M | $205.3M | ||
| Q1 24 | $230.9M | $211.0M |
总资产FORRMED
| Q4 25 | $404.0M | $248.0M | ||
| Q3 25 | $414.2M | $268.2M | ||
| Q2 25 | $436.0M | $269.3M | ||
| Q1 25 | $439.8M | $280.0M | ||
| Q4 24 | $503.9M | $284.2M | ||
| Q3 24 | $505.3M | $291.2M | ||
| Q2 24 | $524.2M | $293.5M | ||
| Q1 24 | $555.7M | $302.8M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-3.2M | $-5.3M |
| 自由现金流经营现金流 - 资本支出 | $-4.3M | $-6.6M |
| 自由现金流率自由现金流/营收 | -4.2% | -8.8% |
| 资本支出强度资本支出/营收 | 1.1% | 1.8% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $18.1M | $1.2M |
8季度趋势，按日历期对齐
经营现金流FORRMED
| Q4 25 | $-3.2M | $-5.3M | ||
| Q3 25 | $1.2M | $12.1M | ||
| Q2 25 | $-3.6M | $-3.4M | ||
| Q1 25 | $26.7M | $3.4M | ||
| Q4 24 | $-1.8M | $-4.9M | ||
| Q3 24 | $264.0K | $9.1M | ||
| Q2 24 | $-2.9M | $13.1M | ||
| Q1 24 | $611.0K | $7.3M |
自由现金流FORRMED
| Q4 25 | $-4.3M | $-6.6M | ||
| Q3 25 | $524.0K | $10.8M | ||
| Q2 25 | $-4.2M | $-4.8M | ||
| Q1 25 | $26.1M | $1.9M | ||
| Q4 24 | $-2.5M | $-7.2M | ||
| Q3 24 | $-223.0K | $7.7M | ||
| Q2 24 | $-3.7M | $11.1M | ||
| Q1 24 | $-815.0K | $5.4M |
自由现金流率FORRMED
| Q4 25 | -4.2% | -8.8% | ||
| Q3 25 | 0.6% | 12.0% | ||
| Q2 25 | -3.8% | -4.5% | ||
| Q1 25 | 29.0% | 1.6% | ||
| Q4 24 | -2.3% | -6.1% | ||
| Q3 24 | -0.2% | 5.5% | ||
| Q2 24 | -3.1% | 6.6% | ||
| Q1 24 | -0.8% | 3.1% |
资本支出强度FORRMED
| Q4 25 | 1.1% | 1.8% | ||
| Q3 25 | 0.7% | 1.5% | ||
| Q2 25 | 0.5% | 1.3% | ||
| Q1 25 | 0.7% | 1.3% | ||
| Q4 24 | 0.6% | 1.9% | ||
| Q3 24 | 0.5% | 1.0% | ||
| Q2 24 | 0.7% | 1.1% | ||
| Q1 24 | 1.4% | 1.1% |
现金转化率FORRMED
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.93× | -1.36× | ||
| Q1 25 | — | — | ||
| Q4 24 | -4.24× | — | ||
| Q3 24 | — | 8.04× | ||
| Q2 24 | -0.46× | — | ||
| Q1 24 | — | 0.88× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FORR
| Research Segment | $82.2M | 81% |
| Consulting Segment | $16.2M | 16% |
| Billable Expenses | $1.5M | 2% |
| Professional Services | $1.4M | 1% |
MED
暂无分部数据
